Avandia (Diabetes Drug): FDA Hearing on 7/30

July 30th is the day that GSK's Avandia is in the spotlight before the FDA.

The FDA said it would gather members from its advisory committees on endocrine and metabolic drugs and on drug safety and risk management. The advisory panel will discuss the cardiovascular risks of the class known as thiazolidinediones, "with a focus on rosiglitazone, as presented by FDA and GlaxoSmithKline," the FDA said.

Stay tuned.